| Basics |
MacroGenics, Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.
|
| IPO Date: |
October 10, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$126.41M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.49 | 3.08%
|
| Avg Daily Range (30 D): |
$0.07 | 4.00%
|
| Avg Daily Range (90 D): |
$0.07 | 4.36%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.55M |
| Avg Daily Volume (30 D): |
.74M |
| Avg Daily Volume (90 D): |
.88M |
| Trade Size |
| Avg Trade Size (Sh.): |
106 |
| Avg Trade Size (Sh.) (30 D): |
188 |
| Avg Trade Size (Sh.) (90 D): |
171 |
| Institutional Trades |
| Total Inst.Trades: |
2,271 |
| Avg Inst. Trade: |
$1.67M |
| Avg Inst. Trade (30 D): |
$2.7M |
| Avg Inst. Trade (90 D): |
$2.7M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.72M |
| Avg Closing Trade (30 D): |
$6.35M |
| Avg Closing Trade (90 D): |
$6.35M |
| Avg Closing Volume: |
111.6K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.58
|
$-.57
|
$-.65
|
|
Diluted EPS
|
$-.58
|
$-.57
|
$-.65
|
|
Revenue
|
$ 165.49M
|
$ 22.24M
|
$ 13.19M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -36.4M
|
$ -36.25M
|
$ -41.04M
|
|
Operating Income / Loss
|
$ -78.03M
|
$ -36.76M
|
$ -42.62M
|
|
Cost of Revenue
|
$ .4M
|
$ M
|
$ M
|
|
Net Cash Flow
|
$ 46.75M
|
$ -14.88M
|
$ -37.27M
|
|
PE Ratio
|
|
|
|
|
|
|
